Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Summit Therapeutics Inc (NASDAQ:SMMT) and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) progressed after EGFR-TKI treatment.

Akeso said that the clinical trial’s final overall survival (OS) analysis showed that ivonescimab met the OS clinical endpoint.

A "statistically significant and clinically meaningful" overall survival (OS) benefit has been observed in the final analysis of ivonescimab's phase 3 HARMONi-A study, Akeso said Tuesday in its half-year report.

Detailed results of this study will be presented at an upcoming medical conference.

Also Read: AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment

The companies shared topline data from the Phase 3 HARMONi trial of ivonescimab plus platinum-doublet chemotherapy compared to placebo plus platinum-doublet chemotherapy met the progression-free survival (PFS) primary endpoint and showed a positive trend ...